EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Zydus Lifesciences Limited (ZYDUSLIFE) fair value: what the stock is really worth

We calculate from audited financials what Zydus Lifesciences Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · IN · ISIN INE010B01027

ZL Some data Sep 18, 2026

Zydus Lifesciences Limited

ZYDUSLIFE · NSE

Weakest SetupStrongly overvalued and low quality.

!Fair value ₹685.94 · Strongly overvalued (−41%)
!Quality 48/100
!Expensive Growth (revenue 5y +13.5 %/yr)
✓Solidly profitable · 18.6% net margin (TTM)
!Low debt · negative free cash flow
·0.09% dividend yield
!Trails peers (5/13)
!Moderate moat 64/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range ₹510.82 to ₹1,845
!Weak on dividend: 2 out of 100
Watch Zydus Lifesciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,287 ₹319.36 Fair Value ₹685.94 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.

How to read this chart

60‑month range ₹319.36 – ₹1,287 · fair‑value band ₹510.82 – ₹1,845 · the ₹1,161 price screens above the ₹685.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products.

Show more

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Stock analysis

Zydus Lifesciences Limited (ZYDUSLIFE) currently trades at ₹1,161, while our model-based Fair Value estimate is ₹685.94, implying the stock looks roughly 69.3% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹1,075 per share, and 1 of the 17 models we run sit above the ₹1,161 price.

Bear case: the Asset-Based group reads lowest at ₹182.10, and 16 of the 17 models stay below the price. Evidence for this calculation is medium.

Scenario range: ₹510.82 (bear) to ₹1,845 (bull), the price of ₹1,161 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Zydus Lifesciences Limited reported revenue of ₹271B in FY2026 versus ₹151B in FY2022, a compound +15.8%/yr. Reported net income was ₹50.4B in FY2026, compounding +2.9%/yr from FY2022.

Key figures

Market cap ₹1.2T (≈ $12.3B) · P/E ratio 23.2 · P/S ratio 4.31 · EPS (TTM) ₹50.06 · Dividend yield 0.1% · Net margin 18.6% · Return on equity 18.3% · Return on assets (EBIT) 20.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (medium confidence).

What moves the price

The share trades near its 52-week high and 39% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at −41%, ZYDUSLIFE screens richer than that median.

Fair Value models

Bear ₹510.82 Fair Value ₹685.94 Bull ₹1,845
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹23.54 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV ₹402.48 ₹476.64 ₹542.56 74
Owner Earnings ₹420.86 ₹846.85 ₹1,661 72
ROIC Compounder ₹465.15 ₹674.00 ₹948.71 71
All 17 models by family
DCF Models
Owner Earnings ₹420.86 ₹846.85 ₹1,661 72
Earnings-Based
Graham-Dodd ₹343.58 ₹1,795 ₹2,484 63
Lynch FV ₹492.33 ₹703.32 ₹914.32 61
PEG = 1.0 ₹492.33 ₹703.32 ₹914.32 57
EPV ₹402.48 ₹476.64 ₹542.56 74
Dividend Discount
Gordon GGM ₹106.68 ₹232.90 ₹391.87 65
DDM Multi-Stage ₹106.68 ₹190.79 ₹242.72 66
Multiples
P/E Multiple ₹833.68 ₹1,112 ₹1,389 63
P/S Multiple ₹644.21 ₹858.94 ₹1,074 58
P/B Multiple ₹644.21 ₹858.94 ₹1,074 55
EV/EBIT ₹721.88 ₹968.43 ₹1,215 66
EV/EBITDA ₹739.57 ₹992.01 ₹1,244 67
EV/Revenue ₹510.14 ₹736.38 ₹962.62 53
Asset-Based
NCAV (Graham) ₹135.90 ₹182.10 ₹271.79 54
Economic Profit
Residual Income ₹348.79 ₹469.20 ₹2,014 64
ROIC Compounder ₹465.15 ₹674.00 ₹948.71 71
Growth Earnings
Growth-Adj P/E ₹752.37 ₹1,075 ₹1,397 67

Open the full fair value analysis →

Notify me when ZYDUSLIFE reaches fair value

Put ZYDUSLIFE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 48/100

Of which business quality 47 · Market factors (momentum, volatility) 71

Profitability 58
Margins and returns on capital today
Quality Growth 34
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 73
Balance sheet, leverage, solvency risk
Investment 21
Disciplined investing over empire-building
Low Volatility 91
Calm price path (market factor)
Momentum 58
Price trend over the last 3–12 months (market factor)
52W Momentum 70
Distance to the 52-week high (market factor)
Net Issuance 83
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.2%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.19% vs 13%, picking up
Profit margin 2004 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 21%

ZYDUSLIFE screens 69% overvalued. Compare with Merck KGaA →

Compare Zydus Lifesciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside +3% · Above median
Profitability
Return on equity (TTM) 18% · Top 25%
Return on assets 8% · Top 25%
Net margin (TTM) 19% · Top 25%
Operating margin (TTM) 18% · Top 25%
Growth and dividend
Revenue growth 16% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 23.2× · Pricier than median
P/B 4.23× · Priciest 25%
P/S (TTM) 4.23× · Priciest 25%
EV/EBITDA 16.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)81 · sector 21
PAST (return on equity)73 · sector 25
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)2 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €131.45 €106.48 −19%
Takeda Pharmaceutical Company TAK $18.64 $11.46 −39%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥43.52 ¥47.87 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,854 ₹1,979 +7%
Galderma Group GALD CHF 154.05 CHF 109.10 −29%
Haleon plc HLN $9.21 $7.56 −18%
Teva Pharmaceutical Industries Limited TEVA $38.53 $15.33 −60%
Sandoz Group SDZ CHF 65.72 CHF 34.14 −48%
Zoetis Inc ZTS $73.00 $104.88 +44%
Hansoh Pharmaceutical Group 3692 HK$34.34 HK$37.77 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zydus Lifesciences Limited · Fair Value
₹685.94 −69%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Zydus Lifesciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/ZYDUSLIFE

Frequently asked questions

Is Zydus Lifesciences Limited (ZYDUSLIFE) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of ₹685.94 versus a price of ₹1,161, about −41% upside (overvalued).
What is the fair value of ZYDUSLIFE?
Our model-based fair value for Zydus Lifesciences Limited is ₹685.94 (as of Sep 18, 2026), built from audited fundamentals. The current price: ₹1,161.
What is the quality score of ZYDUSLIFE?
Zydus Lifesciences Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zydus Lifesciences Limited (ZYDUSLIFE)?
Our model-based price target is the fair value of ₹685.94 (as of Sep 18, 2026) from 17 valuation models. Cautious scenario ₹510.82, optimistic scenario ₹1,845. It is a calculation from audited fundamentals, not an analyst target.
What is the Zydus Lifesciences Limited stock forecast for 2026?
Our models put fair value at ₹685.94, about −41% upside versus a price of ₹1,161 (overvalued). Cautious scenario ₹510.82, optimistic scenario ₹1,845. The calculation is refreshed regularly with new filings.
What is the revenue of Zydus Lifesciences Limited (ZYDUSLIFE)?
Zydus Lifesciences Limited reported trailing-twelve-month revenue of about ₹271B (latest available figure, as of Sep 18, 2026).
Does Zydus Lifesciences Limited pay a dividend?
Zydus Lifesciences Limited currently shows a dividend yield of about 0.09% relative to its recent price (as of Sep 18, 2026).
What is the intrinsic value of Zydus Lifesciences Limited (ZYDUSLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zydus Lifesciences Limited it is ₹685.94 per share (as of Sep 18, 2026), against a price of ₹1,161. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Zydus Lifesciences Limited stock overvalued or undervalued in 2026?
As of Sep 18, 2026, ZYDUSLIFE trades above its calculated fair value: price ₹1,161, fair value ₹685.94, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZYDUSLIFE?
No. The price is what the market pays today (₹1,161); the fair value is what the company's own numbers justify (₹685.94). For Zydus Lifesciences Limited the two are ₹475.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zydus Lifesciences Limited worth?
The market values Zydus Lifesciences Limited at about ₹1.2T (market capitalisation, as of Sep 18, 2026). Per share that is ₹1,161; our models calculate a fair value of ₹685.94 per share.
What do the bullish and bearish scenarios say about ZYDUSLIFE?
Our models span a range for Zydus Lifesciences Limited: cautious scenario ₹510.82, base ₹685.94, optimistic ₹1,845 per share (as of Sep 18, 2026, price ₹1,161). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZYDUSLIFE?
Zydus Lifesciences Limited trades at a price-to-earnings ratio of 23.2 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹685.94 is built from several models across several years. Other multiples: P/B 4.2, P/S 4.2, EV/EBITDA 16.1.
How solid is the balance sheet of Zydus Lifesciences Limited (ZYDUSLIFE)?
Balance-sheet figures for Zydus Lifesciences Limited (as of Sep 18, 2026): return on equity 18.3%, debt of 0.12 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ZYDUSLIFE from its 52-week high?
Zydus Lifesciences Limited trades at ₹1,161, about 4% below its 52-week high of ₹1,116 and 39% above the low of ₹835.50 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of ₹685.94 is for.
Which stocks are comparable to Zydus Lifesciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zydus Lifesciences Limited stock attractive at the current price?
The data as of Sep 18, 2026: price ₹1,161, calculated fair value ₹685.94 (−41%), Quality Score 48/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZYDUSLIFE calculated?
We run Zydus Lifesciences Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹685.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Zydus Lifesciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zydus Lifesciences Limited (ZYDUSLIFE)?
The closing price on Sep 21, 2026 was ₹1,161. Our model-based fair value is ₹685.94, about −41% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zydus Lifesciences Limited right now?
The model range is unusually wide (₹510.82 to ₹1,845). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Zydus Lifesciences Limited (ZYDUSLIFE) come from?
Earnings per share at Zydus Lifesciences Limited grew +12.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +11.1 %, EBIT margin −0.5 %, tax rate −1.6 %, residual (interest, one-offs) +3.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Zydus Lifesciences Limited

How large is the market capitalisation of Zydus Lifesciences Limited (ZYDUSLIFE)?
The market capitalisation of Zydus Lifesciences Limited is ₹1.2T (≈ $12.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zydus Lifesciences Limited (ZYDUSLIFE)?
The price-to-sales ratio of Zydus Lifesciences Limited is 4.31 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zydus Lifesciences Limited (ZYDUSLIFE)?
Earnings per share at Zydus Lifesciences Limited are ₹50.06 (price ÷ EPS = P/E 23.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zydus Lifesciences Limited (ZYDUSLIFE)?
The dividend yield of Zydus Lifesciences Limited is 0.1% (payout 2.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zydus Lifesciences Limited (ZYDUSLIFE)?
The net margin of Zydus Lifesciences Limited is 18.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zydus Lifesciences Limited (ZYDUSLIFE)?
The return on equity (ROE) of Zydus Lifesciences Limited is 18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zydus Lifesciences Limited (ZYDUSLIFE)?
On an EBIT basis the return on assets of Zydus Lifesciences Limited is 20.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zydus Lifesciences Limited (ZYDUSLIFE)?
The operating margin of Zydus Lifesciences Limited is 18.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zydus Lifesciences Limited (ZYDUSLIFE)?
Revenue at Zydus Lifesciences Limited is growing +16.2% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zydus Lifesciences Limited (ZYDUSLIFE)?
Earnings per share at Zydus Lifesciences Limited are growing +8.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zydus Lifesciences Limited (ZYDUSLIFE) generate?
The free cash flow of Zydus Lifesciences Limited is −₹12.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zydus Lifesciences Limited (ZYDUSLIFE) carry?
The net debt of Zydus Lifesciences Limited is ₹111B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zydus Lifesciences Limited in the live analysis

One click puts Zydus Lifesciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.